Arestat™ Protein Stabilisation Technology
Arestat™ comprises two fundamentally different aspects of our platform stabilisation technology – Arestat-T™ and Arestat-R™. Both utilise excipients and buffers approved by the FDA and EMEA in an unconventional manner to achieve the desired stability.
Both are available for licensing for therapeutic proteins, vaccines, medial devices and diagnostics.
Papers / Posters

Publications:

Jezek J, Chen D, Watson L, Crawford J, Perkins S, Tyagi A, Jones-Braun L. A heat-stable hepatitis B vaccine formulation. Human Vaccines (2009), 5(8), 529-35.


Jones-Braun L, Jezek J, Peterson S, Tyagi A, Perkins S, Sylvester D, Guy M, Lal M, Priddy S, Plzak H, Kristensen D, Chen D. Characterization of a thermostable hepatitis B vaccine formulation. Vaccine (2009), 27, 4609-14.

Selected posters:

BioProcess International, Dusseldorf, Germany (April 2009): Superior stability of biological molecules can be achieved in unconventional formulations.


BioProcess International, Raleigh, USA (October 2009): Reformulation of existing protein therapeutics to minimize aggregation and improve their stability.


PEPTalk, San Diego, USA (January 2010): Reformulation of existing protein therapeutics to minimize aggregation and improve their stability.


BioProcess International, Vienna, Austria (May 2010): Novel formulations of protein biologics with considerably reduced rate of aggregation.